NCT02137954

Efficacy of Lidocaine Versus Placebo in Palliative Care Patients With Opioid-refractory Cancer Pain With Neuropathic Component: a Multicenter, Prospective, Double-blind Randomized Placebo-controlled Study.

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Assistance Publique Hopitaux De Marseille · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, prospective, randomized, placebo-controlled, double-blind, two-parallel groups study comparing lidocaine (experimental group) to placebo (control group). The study protocol was elaborated using the recommendations of the Consolidated Standards of Reporting Trials (CONSORT) Statement.

Conditions

• Cancer
• Pain With Neuropathic Component

Interventions

Type	Name	Description
DRUG	Lidocaine
DRUG	Placebo

Timeline

• Start date: 2014-05-01
• Primary completion: 2016-06-01
• Completion: 2016-09-01
• First posted: 2014-05-14
• Last updated: 2015-08-28

Locations

1 site across 1 country: France